Baltimore-based startup Eneura Inc. has raised a $17 million series D round to market its handheld transcranial magnetic stimulation device. Last fall, the FDA cleared the daily, single use device, known as the sTMS mini, for migraine prevention. That makes it the only treatment – drug or device – that's been given a nod from the regulator for both acute migraine treatment and prevention. Read More
